Literature DB >> 15279046

The global costs of schizophrenia.

Martin Knapp1, Roshni Mangalore, Judit Simon.   

Abstract

Schizophrenia is a chronic disease associated with a significant and long-lasting health, social, and financial burden, not only for patients but also for families, other caregivers, and the wider society. Many national and local studies have sought to estimate the societal burden of the illness--or some components of it--in monetary terms. Findings vary. We systematically reviewed the literature to locate all existing international estimates to date. Sixty-two relevant studies were found and summarized. Within- and between-country differences were analyzed descriptively. Despite the wide diversity of data sets and methods applied, all cost-of-illness estimates highlight the heavy societal burden of schizophrenia. Such information helps us to understand the health, health care, economic, and policy importance of schizophrenia, and to better interpret and explain the large within- and across-country differences that exist.

Entities:  

Mesh:

Year:  2004        PMID: 15279046     DOI: 10.1093/oxfordjournals.schbul.a007078

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  143 in total

1.  When functional capacity and real-world functioning converge: the role of self-efficacy.

Authors:  Veronica Cardenas; Stephanie Abel; Christopher R Bowie; Denisse Tiznado; Colin A Depp; Thomas L Patterson; Dilip V Jeste; Brent T Mausbach
Journal:  Schizophr Bull       Date:  2012-02-10       Impact factor: 9.306

2.  High loading of polygenic risk in cases with chronic schizophrenia.

Authors:  S M Meier; E Agerbo; R Maier; C B Pedersen; M Lang; J Grove; M V Hollegaard; D Demontis; B B Trabjerg; C Hjorthøj; S Ripke; F Degenhardt; M M Nöthen; D Rujescu; W Maier; T Werge; O Mors; D M Hougaard; A D Børglum; N R Wray; M Rietschel; M Nordentoft; P B Mortensen; M Mattheisen
Journal:  Mol Psychiatry       Date:  2015-09-01       Impact factor: 15.992

3.  Contributions of early cortical processing and reading ability to functional status in individuals at clinical high risk for psychosis.

Authors:  Ricardo E Carrión; Barbara A Cornblatt; Danielle McLaughlin; Jeremy Chang; Andrea M Auther; Ruth H Olsen; Daniel C Javitt
Journal:  Schizophr Res       Date:  2015-02-23       Impact factor: 4.939

Review 4.  Emerging empirical evidence on the ethics of schizophrenia research.

Authors:  Laura B Dunn; Philip J Candilis; Laura Weiss Roberts
Journal:  Schizophr Bull       Date:  2005-10-19       Impact factor: 9.306

Review 5.  Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectiveness models.

Authors:  Alan Haycox
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

6.  Burdens and psychological health of family caregivers of people with schizophrenia in two Chinese metropolitan cities: Hong Kong and Guangzhou.

Authors:  Paul Cw Lam; Petrus Ng; Christopher Tori
Journal:  Community Ment Health J       Date:  2013-06-12

Review 7.  Racial and ethnic disparities in the use of antipsychotic medication: a systematic review and meta-analysis.

Authors:  Joseph H Puyat; Jamie R Daw; Colleen M Cunningham; Michael R Law; Sabrina T Wong; Devon L Greyson; Steven G Morgan
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2013-08-14       Impact factor: 4.328

Review 8.  Postmortem brain: an underutilized substrate for studying severe mental illness.

Authors:  Robert E McCullumsmith; John H Hammond; Dan Shan; James H Meador-Woodruff
Journal:  Neuropsychopharmacology       Date:  2013-10-04       Impact factor: 7.853

9.  The Global Functioning: Social and Role Scales-Further Validation in a Large Sample of Adolescents and Young Adults at Clinical High Risk for Psychosis.

Authors:  Ricardo E Carrión; Andrea M Auther; Danielle McLaughlin; Ruth Olsen; Jean Addington; Carrie E Bearden; Kristin S Cadenhead; Tyrone D Cannon; Daniel H Mathalon; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Scott W Woods; Barbara A Cornblatt
Journal:  Schizophr Bull       Date:  2019-06-18       Impact factor: 9.306

10.  Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data.

Authors:  Simon Frey; Roland Linder; Georg Juckel; Tom Stargardt
Journal:  Eur J Health Econ       Date:  2013-02-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.